Related Experiment Video
Updated: Jun 12, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Targeted treatment and new agents in diffuse large B cell lymphoma
Sophie Dupire1, Bertrand Coiffier
1Hematology Department, Hospices Civils de Lyon and Université Lyon 1, Lyon, France.
International Journal of Hematology
|June 19, 2010
Summary
The introduction of rituximab revolutionized diffuse large B cell lymphoma (DLBCL) treatment, paving the way for novel targeted therapies including monoclonal antibodies and small molecules. These advancements offer new hope for improving patient outcomes in DLBCL.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Diffuse large B cell lymphoma (DLBCL) outcomes have significantly improved with targeted therapies.
- Rituximab marked the first targeted therapy, initiating a new era in DLBCL treatment.
- Subsequent research has focused on novel antibodies and small molecules targeting key cellular pathways.
Purpose of the Study:
- To review major clinical study results for new targeted agents in DLBCL patients.
- To present pre-clinical study findings for agents newly entering clinical evaluation.
- To highlight advancements in DLBCL therapeutic strategies.
Main Methods:
- Review of clinical studies on novel monoclonal antibodies and small molecules in DLBCL.
- Analysis of pre-clinical data for emerging DLBCL therapeutics.
- Focus on agents targeting cell surface receptors and key cellular machinery.
Main Results:
- Rituximab in combination with chemotherapy has transformed DLBCL patient outcomes.
- Numerous new therapeutic small molecules target various pathways like apoptosis and proteasome.
- Monoclonal antibodies target specific cell surface markers such as CD20, CD22, and CD19.
Conclusions:
- Targeted therapies, including monoclonal antibodies and small molecules, represent a significant advancement in DLBCL treatment.
- Ongoing research continues to explore novel agents and pathways for improved DLBCL management.
- The development of targeted therapies has fundamentally changed the therapeutic landscape for DLBCL.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...